Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹105 Cr
verified against source
Revenue YoY
31%
reported change
EBITDA
₹16.25 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Platinum Industries reported Q3 FY26 standalone revenue of ₹102.62 crore, up 31% YoY, driven by strong CPVC demand and capacity expansion. PAT grew 18% YoY to ₹12.93 crore, though EBITDA margin contracted to 15.8% due to higher CPVC mix and new plant costs. Management guided for >40% revenue growth in FY27 and a 35% CAGR through FY29, supported by the Palar facility ramp-up (CPVC at 60-65% utilization) and Egypt plant commissioning by September 2026. The company also entered pharma via a new subsidiary. Risks include margin pressure from product mix shift and execution delays in Egypt.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects standalone revenue growth exceeding 40% in FY27, driven by Palar ramp-up and Egypt commissioning.
- Company targets a 35% compound annual growth rate over the next three years, excluding pharma business.
- Egypt plant construction to complete by end of May 2026, pre-commissioning in June, commercial production by September 2026.
- New pharma subsidiary (Rivardu Life Sciences) expected to generate revenue in FY27, though no specific figures provided.
Risks flagged
- Higher CPVC sales, which carry lower margins, have compressed overall EBITDA margins from 23% in FY24 to ~15% currently.
- Egypt plant already delayed by 9-12 months; further delays could push revenue contribution beyond FY27.
- Promoter sold ~0.87% stake in Q3 for personal loans, raising concerns about future dilution.
- Global shift away from lead stabilizers could impact Egypt's lead-focused capacity, though management claims machines can be converted.
Key quotes
- We expect to accelerate our growth trajectory targeting more than 40% revenue growth in financial year 2027 and a 35% CAGR from financial year 2026 to financial year 2029.
- The product the new product has its own life cycle in terms of getting to its mature state... we were very successful in two quarters back to find the alternatives to make the formulation more effective.
- If you talk about the strategic location is closer to the western world... 20 FTA agreements means almost 130 countries can import from us duty-free.
Research modules